ESC 25: The VICTOR & VICTORIA Pooled Analysis скачать в хорошем качестве

ESC 25: The VICTOR & VICTORIA Pooled Analysis

ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial. Dr Javed Butler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection fraction. VICTORIA included patients with worsening heart failure, whilst VICTOR examined ambulatory patients without recent HF worsening. Findings showed that vericiguat significantly reduced the risk of cardiovascular mortality and HF hospitalisations, as well as all-cause mortality across both trials, suggesting vericiguat could be a useful treatment option across a wide spectrum of patients. Interview Questions: 1. What is the current research landscape for vericiguat treatment for HFrEF, and what was the reasoning behind the study? 2. What was the study design and patient population? 3. What were the key findings? 4. What are the take-home messages for practice? 5. What further research is needed in this area? Recorded on-site at ESC Congress 2025, Madrid. Editors: Jordan Rance, Yazmin Sadik. Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh. Support: This is an independent interview produced by Radcliffe Cardiology. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook:   / radcliffecardiology   Follow us on X: https://x.com/radcliffeCARDIO